3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
5
Melanoma
2
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Moderate Hepatic Impairment
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Meningioma
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Leukemia
1
Healthy Participants
1
Endometrial Neoplasms
1
Disease Progression
1
Chondrosarcoma
1
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
1
Interventions
Cyclophosphamide
27
fludarabine
18
Rituximab
17
obinutuzumab
11
venetoclax
9
Bendamustine Hydrochloride
9
Lenalidomide
8
zanubrutinib
6
Prednisone
6
Doxorubicin
6
Blood Specimen Collection
6
pembrolizumab
5
fludarabine phosphate
5
Biopsy
5
ibrutinib
4
glofitamab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Exercise
4
loncastuximab tesirine
3
gamma-Globulins
3
axicabtagene ciloleucel
3
acalabrutinib
3
Temozolomide
3
Surveys and Questionnaires
3
Palliative Care
3
Mycophenolic Acid
3
Methotrexate
3
Mesna
3
Magnetic Resonance Spectroscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma
×
capivasertib
×
Clear all
NCT07294677
2026-03-04
CAVALRY
University of Chicago
Phase 1/2
Recruiting
104 enrolled